Combination Therapy Shows Promise in High-Risk Prostate Cancer, Study Finds
A large international clinical trial has found that adding the drug apalutamide to standard hormone therapy before and after prostate cancer surgery significantly improves outcomes for men with…
Read the full articleYou might also wanna read
Immunotherapy Strategy Shows Promise for Deadly Brain Cancer
news.northwestern.edu·9d ago
Immune Biomarkers May Predict Response to Bladder Cancer Treatment
news.northwestern.edu·1mo ago
Blood Test May Predict Immunotherapy Response in Head and Neck Cancer
news.northwestern.edu·1mo ago
New Analytic Method Reveals ‘Building Blocks’ of Brain Activity
news.northwestern.edu·11h ago
Independent researcher recounts submission nightmare with BioEssays journal over preprint on alternative evolution
oxylipins.substack.com·1d ago
Examining the Impact of Aging on Critical Cellular Processes
news.northwestern.edu·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.